Background: Sensitive diagnostic testing is critical in responses to mumps outbreaks. PCR testing of buccal swabs is the most sensitive diagnostic test, but IgM serology remains standard in much of the United States. We provided testing guidance stressing use of mumps PCR to ambulatory clinics and emergency departments in addition to the standard serologic testing for acute mumps beginning in 2018. We compared the performance of PCR and IgM serology to assess cases of parotitis presenting during a community outbreak of mumps in fall 2019 associated with a university in Charleston, SC. Methods: All patients tested for mumps who presented to our facility (ER and ambulatory clinics) with mumps PCR and/or mumps IgM ordered between September 2019 and January 2020 were included. Mumps PCRs were sent to a commercial reference laboratory (ARUP). Confirmed cases were defined as having a positive mumps PCR and/or IgM with parotitis. Clinical characteristics of mumps patients including age, duration of symptoms, MMR history, and association with the university were obtained by chart review. Results: Mumps was confirmed in 15 of 44 tested patients (34%), with 15 of 15 mumps patients (100%) having positive PCR and 1 of 15 patients (7%) and 1 of 15 patients (7%) having positive and equivocal mumps IgM serologies, respectively. Only 1 patient who did not meet our mumps case definition (no CT imaging evidence of parotitis, no fevers, chronic sinus symptoms) had a positive PCR and had recent receipt of a third MMR dose in response to the ongoing outbreak. Median age for mumps patients was 22 years (range, 15–48) with 8 of 15 cases (53%) detected among university students and an additional 2 cases having close connections to the university associated with the outbreak. Only 1 of 15 mumps patients (6.7%) was febrile at presentation (median temperature, 37.2°C) and mumps cases presented for testing ≤3 days for 7 of 15 cases (47%) (range, 0–13 days from symptom onset). No cases were diagnosed by IgM only, and 10 of 15 mumps cases had some recollection of remote MMR immunization, whereas 6 of 15 (40%) had 2 documented MMR doses at <5 years of age. Conclusion: Serologic IgM testing for diagnosis of mumps appears insensitive for detection of cases in outbreaks within highly immunized adult patients. Although our recommended shift to PCR likely enhanced case finding during this outbreak, the potential for false-positive PCRs due to vaccine strain shedding following third-dose MMR immunization may also be considered a threat to the specificity of the test during outbreak situations.

Funding: None

Disclosures: None

Background: We previously showed that ~25% of Veterans’ Affairs (VA) long-term care facility (LTCF) residents had 1 or more indwelling medical devices. Of these devices, 36% were indwelling urinary catheters, 18% were percutaneous gastrostomy tubes, 12% were peripherally inserted central catheters, 8% were suprapubic urinary catheters, and 6% were peripheral intravenous catheters. Approximately 11% of those with an indwelling device developed an LTCF-acquired infection, compared to 3.5% of those without a device. Methicillin-resistant Staphylococcus aureus (MRSA) is a targeted multidrug-resistant organism (MDRO) in all VA LTCFs nationwide. All admissions to VA LTCFs are screened for MRSA carriage upon admission and, since 2013, those that screen positive (~21%) are placed in VA enhanced barrier precautions (EBPs). VA EBPs require that all healthcare workers entering a resident’s bedroom don gowns and gloves for specific activities likely to be associated with contamination of the worker’s hands and clothes. With proper hand hygiene and clean clothing, the colonized resident is encouraged to leave their bedroom and participate fully in all LTCF activities. In July 2019, the US Centers for Disease Control and Prevention (CDC) recommended the use of EBPs for all residents in LTCFs with a wound or device regardless of their colonization status if a resident is identified within the facility with novel or targeted MDROs including panresistant organisms, carbapenemase-producing gram-negative bacteria, and Candida auris. Methods: We assessed the potential impact of this recommendation on VA LTCFs by asking our 133 LTCFs to do a 1-day point-prevalence survey. Results: In total, 63 sites (47%) responded. On the survey day, there were 4,777 residents in the participating facilities, of whom 891 (18.7%) were under EBPs or contact precautions (CPs) for MRSA or other MDROs. Moreover, 963 (20.2%) residents (not already in EBP or CP) had a wound or an indwelling device such as central venous catheter, urinary catheter, feeding tube, tracheostomy or were on a ventilator (if >1 device, resident counted only once). If newly published CDC recommendations were implemented for novel or targeted MDRO precautions in VA LTCFs nationwide, 1,854 residents (38.8%) in VA LTCFs would be placed under EBPs or CPs. Conclusions: In VA LTCFs, adopting the CDC recommendation to place all patients with wounds or indwelling devices under EBPs regardless of colonization status would increase the percentage of residents on transmission-based precautions to ~40% (nearly doubling those in an isolation precaution status).

Funding: None

Disclosures: None